Metoprolol tartrate - Generic Drug Details

What are the generic drug sources for metoprolol tartrate and what is the scope of freedom to operate?

Metoprolol tartrate is the generic ingredient in two branded drugs marketed by Novartis, Am Regent, Baxter Hlthcare Corp, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Luitpold, Sandoz, Steriscience Speclts, Watson Labs, Validus Pharms, Alembic Pharms Ltd, Apothecon, Aurobindo Pharma, Chartwell Rx, Heritage Pharma, Ipca Labs Ltd, Mylan, Norvium Bioscience, Purepac Pharm, Renata, Rubicon, Sun Pharm Inds Inc, Sun Pharm Industries, Teva, Teva Pharms, Youngtech Pharms Inc, and Zydus Pharms, and is included in thirty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for metoprolol tartrate. Fifty-six suppliers are listed for this compound.

Summary for metoprolol tartrate

US Patents:	0
Tradenames:	2
Applicants:	30
NDAs:	35
Drug Master File Entries:	27
Finished Product Suppliers / Packagers:	56
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	25
Patent Applications:	2,392
Drug Prices:	Drug price trends for metoprolol tartrate
Drug Sales Revenues:	Drug sales revenues for metoprolol tartrate
What excipients (inactive ingredients) are in metoprolol tartrate?	metoprolol tartrate excipients list
DailyMed Link:	metoprolol tartrate at DailyMed

See drug prices for metoprolol tartrate

See drug sales revenues for metoprolol tartrate

Recent Clinical Trials for metoprolol tartrate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Consorcio Centro de Investigación Biomédica en Red (CIBER)	Phase 3
Instituto de Salud Carlos III	Phase 3
European Commission	Phase 3

See all metoprolol tartrate clinical trials

Pharmacology for metoprolol tartrate

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for metoprolol tartrate

C07AB	Beta blocking agents, selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for metoprolol tartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	LOPRESSOR	metoprolol tartrate	TABLET;ORAL	017963-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Zydus Pharms	METOPROLOL TARTRATE	metoprolol tartrate	TABLET;ORAL	212402-001	Apr 19, 2023		DISCN	No	No
Watson Labs	METOPROLOL TARTRATE	metoprolol tartrate	INJECTABLE;INJECTION	074032-001	Dec 21, 1993		DISCN	No	No
Fresenius Kabi Usa	METOPROLOL TARTRATE	metoprolol tartrate	INJECTABLE;INJECTION	091045-001	Oct 25, 2010	AP	RX	No	No

Expired US Patents for metoprolol tartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	LOPRESSOR	metoprolol tartrate	TABLET;ORAL	017963-002	Approved Prior to Jan 1, 1982
Novartis	LOPRESSOR	metoprolol tartrate	INJECTABLE;INJECTION	018704-001	Mar 30, 1984
Validus Pharms	LOPRESSOR	metoprolol tartrate	TABLET;ORAL	017963-002	Approved Prior to Jan 1, 1982
Validus Pharms	LOPRESSOR	metoprolol tartrate	TABLET;ORAL	017963-001	Approved Prior to Jan 1, 1982

Metoprolol tartrate Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Metoprolol Tartrate

Introduction to Metoprolol Tartrate

Metoprolol tartrate is a beta-blocker medication widely used to treat various cardiovascular conditions, including hypertension, angina, heart attacks, and other heart-related diseases. It operates by reducing the impact of certain natural substances, such as epinephrine, on the heart and blood vessels[4].

Market Size and Growth

The global metoprolol tartrate market is projected to experience significant growth over the coming years. As of 2023, the market size was valued at approximately USD 6.55 billion and is expected to reach USD 8.81 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 3.8% during the forecast period[1].

Another report indicates that the market size was valued at USD 6.31 billion in 2023 and is projected to reach USD 8.6 billion by 2032, with a CAGR of 3.5% from 2024 to 2032[3].

Geographical Analysis

Geographically, the metoprolol tartrate market is dominated by North America, primarily due to the high prevalence of cardiovascular diseases, well-developed healthcare systems, and higher healthcare spending in this region. The increasing life expectancy and high prevalence of obesity and low-activity levels further contribute to the demand for metoprolol tartrate in North America[3][4].

The Asia-Pacific region is also expected to grow significantly during the forecast period, driven by increasing regional investments and the expanding application of metoprolol tartrate to treat hypertension and angina[1][4].

Market Drivers

Several factors are driving the growth of the metoprolol tartrate market:

Rising Prevalence of Cardiovascular Diseases

The global population's aging and lifestyle factors are contributing to an increase in cardiovascular diseases, thereby increasing the demand for medications like metoprolol tartrate. This trend presents opportunities for pharmaceutical companies to expand their market share and develop innovative formulations[1].

Patient Education and Adherence

Investing in patient education and adherence programs can improve patient outcomes and loyalty. By helping patients understand the importance of adhering to their metoprolol tartrate regimen, companies can enhance the effectiveness of the treatment and reduce the risk of non-adherence[1].

Collaboration with Healthcare Providers

Building collaborative relationships with healthcare providers, hospitals, and clinics can secure preferred formulary status for metoprolol tartrate, ensuring its inclusion in treatment protocols. This collaboration can also lead to better patient care and increased market penetration[1].

Market Restraints

Despite the growth drivers, there are several challenges that the metoprolol tartrate market faces:

Healthcare System Reimbursement

One of the significant restraints is the complexity and variability of healthcare system reimbursements. Changes in reimbursement policies and the stringent regulatory environment can affect the market's growth[1].

Side Effects and Regulatory Framework

The rising side effects associated with metoprolol tartrate and the binding government regulations on its use are major factors hampering the market's growth. These factors necessitate careful monitoring and compliance by pharmaceutical companies[4].

Market Segmentation

The metoprolol tartrate market is segmented based on several factors:

Route of Administration

The market is segmented into oral tablets and injectable solutions. Oral tablets dominate the market due to their ease of administration and growing demand[1].

Application

Metoprolol tartrate is used to treat various conditions, including hypertension, cardiovascular diseases, and angina. The application segment is crucial in understanding the diverse uses of the medication[1][4].

Distribution Channel

The distribution channels include hospitals, retail pharmacies, and online pharmacies. The ease of access through these channels contributes to the market's growth[1].

Pricing and Cost Analysis

The cost of metoprolol tartrate varies based on the dosage, form (oral or injectable), and the pharmacy. For example:

• The cost for a 25 mg oral tablet can be around $10 for a supply of 14 tablets[2].
• The cost for a 100 mg oral tablet can range from $15.46 for 30 tablets to $72.36 for 1000 tablets, depending on the pharmacy and availability[2].

The prices also differ between metoprolol tartrate and metoprolol succinate, with the latter being an extended-release form[5].

Key Players and Competitive Landscape

The metoprolol tartrate market is competitive, with several major players operating globally. These companies are adopting strategies such as product launches, expansions, and inorganic growth through partnerships and collaborations to enhance their market share. Detailed analysis of the strengths, weaknesses, and opportunities of these prominent players is crucial for understanding the market dynamics[4].

Regional Insights

• North America: Dominates the market due to the high prevalence of cardiovascular diseases and well-developed healthcare systems[3][4].
• Asia-Pacific: Expected to grow rapidly due to increasing regional investments and the expanding application of metoprolol tartrate[1][4].
• Europe: Also a significant market, driven by the rising incidence of heart diseases and the availability of advanced healthcare facilities[1].

Conclusion

The metoprolol tartrate market is poised for significant growth driven by the increasing prevalence of cardiovascular diseases, patient education and adherence programs, and collaborations with healthcare providers. However, the market faces challenges such as healthcare system reimbursements, side effects, and regulatory frameworks.

Key Takeaways

• The global metoprolol tartrate market is expected to grow from USD 6.55 billion in 2023 to USD 8.81 billion by 2031.
• North America dominates the market due to high prevalence of cardiovascular diseases and well-developed healthcare systems.
• The Asia-Pacific region is expected to grow rapidly due to increasing regional investments.
• Patient education and adherence programs are crucial for market growth.
• Healthcare system reimbursements and side effects are significant restraints.

Frequently Asked Questions (FAQs)

1. What is metoprolol tartrate used for?

Metoprolol tartrate is used to treat various cardiovascular conditions, including hypertension, angina, heart attacks, and other heart-related diseases[4].

2. What is the difference between metoprolol tartrate and metoprolol succinate?

Metoprolol tartrate is an immediate-release form, while metoprolol succinate is an extended-release form that slowly releases its dose over time[5].

3. Which region dominates the metoprolol tartrate market?

North America dominates the metoprolol tartrate market due to the high prevalence of cardiovascular diseases and well-developed healthcare systems[3][4].

4. What are the key drivers of the metoprolol tartrate market?

The key drivers include the rising prevalence of cardiovascular diseases, patient education and adherence programs, and collaborations with healthcare providers[1].

5. What are the major restraints of the metoprolol tartrate market?

The major restraints include healthcare system reimbursements, side effects associated with the medication, and regulatory frameworks[1][4].

Sources:

1. Data Bridge Market Research - Global Metoprolol Tartrate Market Size, Evaluating Share & Forecast By 2031
2. Drugs.com - Metoprolol Tartrate Prices, Coupons, Copay Cards & Patient Assistance
3. Introspective Market Research - Metoprolol Tartrate Market-Current Analysis by Market Share
4. IndustryARC - Metoprolol Tartrate Market Size Report, 2022-2027
5. MedicalNewsToday - Metoprolol cost 2024: Coupons and more